U.S. Patent No. 10,265,362 B2 (‘362) issued on April 23, 2019, for “Ingestible Films Having Substances From Hemp or Cannabis.” It was issued to applicant/inventor Scott Schaneville, of St. Petersburg, Florida. Figure 1-2 illustrates the claimed invention: The ‘362 patent discloses a new system for cannabis medical drug delivery, specifically through mucosal oral administration of …
Category: patent
CannabIP: U.S. Patent No. 10,239,808 B1
U.S. Patent No. 10,239,808 B1 (‘808) issued on March 26, 2019, for “Cannabis Extracts.” It was issued to inventors Jacob Black of New Haven, Connecticut, Ryan Beigle of Littleton, Colorado, and Alex Mateo of Lakewood, Colorado. The applicant/assignee is Canopy Holdings, LLC of Littleton, Colorado, the food and agriculture company (not to confused with the …
CannabIP: Second Circuit Refuses to Dismiss CBD Reclassification Case
On May 30, 2019, the Court of Appeals for the Second Circuit in Washington v. Barr,[1] refused to dismiss outright a case where the plaintiffs alleged marijuana’s classification on the Drug Enforcement Agency (DEA)’s Schedule I list of the Controlled Substance Act (CSA) of the poses a “serious, life-of-death threat to their health.” The Second …
SCOTUS Watch: Government Is Not a Person for Purposes of AIA
On June 10, 2019, the U.S. Supreme Court overturned the Court of Appeals for the Federal Circuit in Return Mail, Inc. v. United States Postal Service,[1] in which the Court held that the Government was not a “person” for definitions of the America Invents Act (AIA). The case originates from Return Mail’s patent, U.S. Patent …
TechPat: Justice Department Reviews Truvada Manufacturer for Possible Patent Violations
The U.S. Department of Justice (DOJ) has recently opened an investigation into possible violations of Gilead Sciences, Inc.’s exclusive license with the U.S. Government of its blockbuster HIV drug, TRUVADA®. Truvada is the pre-exposure prophylaxis (PrEP) which has been shown to prevent HIV infections. Because of its exclusive license, Gilead is the only manufacturer of …
CannabIP: U.S. Patent No. 10,179,694 B2
U.S. Patent No. 10,179,694 B2 (‘694) issued on November 20, 2018, for “Constant Illuminated Tamper-Resistant Plant Shipping Container.” It was issued to applicant/inventor Larry D. Fenner, Jr. of Bellingham, Washington. The assignee is THC Acquisition Corp. of Kelowna, British Columbia. THC BioMed Ltd. is the parent company, a Canadian medical cannabis company. Figure 1 illustrates …
TechPat: U.S. Patent No. D844,022 S1
U.S. Patent No. D844,022 S (‘022) issued on March 26, 2019, for “Computing Device Display Screen with Graphical User Interface.” It was issued to inventor Shalin Amin, of San Francisco, California. The applicant/assignee is Uber, Inc. of San Francisco, California, a ride share/ride hailing company. This patent is a design patent under 35 U.S.C. §171, …
Fed Circuit Watch: EV Battery Claims Found Patent-Ineligible
What had opened with a promise of clarity for patent subject matter eligibility under 35 U.S.C. §101 took a detour with the ChargePoint, Inc. v. SemaConnect, Inc.,[1] decision issued on March 28 2019, by the Court of Appeals for the Federal Circuit. Four patents were at-issue, all owned by ChargePoint: U.S. Patent Nos. 8,138,715 (‘715), …
Fed Circuit Watch: Treatment Method Claims Found Patent-Eligible
The third treatment method case in the last year that was challenged as patent-ineligible subject matter under 35 U.S.C. §101 has been found eligible by the Court of Appeals for the Federal Circuit, in a recent case, Endo Pharms. Inc. v. Teva Pharms. USA, Inc.,[1] decided March 28, 2019. Endo owns U.S. Patent No. 8,808,737 …
Fed Circuit Watch: Cat’s Out of the Bag: Continuous Reduction to Practice is Reasonable Diligence
Arctic Cat Inc. has been involved in a few patent-related cases in recent years, including one case from 2018 which we discussed on this blog dealing with the law of obviousness’s motivation to combine analysis under 35 U.S.C. §103. Its most recent foray into the Court of Appeals for the Federal Circuit resulted in its …